<SEC-DOCUMENT>0001104659-21-091679.txt : 20210713
<SEC-HEADER>0001104659-21-091679.hdr.sgml : 20210713
<ACCEPTANCE-DATETIME>20210713160521
ACCESSION NUMBER:		0001104659-21-091679
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210713
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210713
DATE AS OF CHANGE:		20210713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36598
		FILM NUMBER:		211087932

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(608) 441-8120

	MAIL ADDRESS:	
		STREET 1:		100 CAMPUS DRIVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2122116d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>July 13, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CELLECTAR
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>(<I>Exact name of registrant as specified in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 32%; font-size: 10pt; font-weight: bold">Delaware</TD><TD STYLE="text-align: center; width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 32%; font-size: 10pt; font-weight: bold">1-36598</TD><TD STYLE="text-align: center; width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 32%; font-size: 10pt; font-weight: bold">04-3321804</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(State or other jurisdiction<BR>
 of incorporation)</TD><TD STYLE="text-align: center; font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(Commission<BR>
 File Number)</TD><TD STYLE="text-align: center; font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center">(I.R.S. Employer<BR>
 Identification No.)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>100
Campus Drive, Florham Park, New Jersey 07932</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>(<I>Address of principal executive offices, and zip code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(608)
441-8120</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT>(<I>Registrant's telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.00001</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLRB</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM 7.01&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGULATION FD
DISCLOSURE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On July 13,
2021, we </FONT>issued a press release announcing that we have expanded our ongoing collaboration with IntoCell Inc., a biotechnology
company based in South Korea. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM 9.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL STATEMENTS AND EXHIBITS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 5%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 75%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="tm2122116d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2122116d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated July 13, 2021, titled &ldquo;Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dated: July 13, 2021</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CELLECTAR BIOSCIENCES, INC.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"> /s/ Dov Elefant</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 42%">Dov Elefant</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Financial Officer</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2122116d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right; text-indent: 0.5in; background-color: white"><IMG SRC="tm2122116d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cellectar
Announces Expansion of Ongoing </B></FONT><B>Collaboration Agreement with IntoCell Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>Preclinical Data Supports
Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FLORHAM
PARK, N.J., July 13, 2021</B></FONT> --&nbsp;Cellectar Biosciences, Inc.&nbsp;(NASDAQ: CLRB), a late-stage clinical biopharmaceutical
company focused on the discovery and development of drugs for the treatment of cancer, today announced that it has expanded its ongoing
collaboration with IntoCell Inc., a biotechnology company based in South Korea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The parties have been
collaborating on combining IntoCell&rsquo;s validated novel Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker chemistry with Cellectar&rsquo;s
validated novel targeting platform, phospholipid ethers (PLEs) to develop new PDCs. IntoCell&rsquo;s platform significantly enhances the
utility of traditional antibody drug conjugate linkers by customizing the entire linker to a specific project. The collaboration has exceeded
the necessary preclinical results to warrant further development and the initiation of Investigational New Drug (IND) enabling studies
with multiple payloads. Cellectar will have the right to globally develop and commercialize any OHPAS containing PDC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&ldquo;Since initiating
our multi-target collaboration, Cellectar has been able to advance various PDC candidates which leverage the differentiated advantages
of IntoCell&rsquo;s technology,&rdquo; said James Caruso, president and CEO of Cellectar. &ldquo;Through this arrangement we are excited
to broaden our research into next-generation targeted therapies and anticipate the development of additional candidates for Cellectar&rsquo;s
growing small molecule PDC pipeline&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&ldquo;We have built
a strong partnership with Cellectar through the multi-target PDC platform collaboration. Our partnership has validated the use of PLEs
with our novel OHPAS linker platform technology and the competitive potential of these innovative PDCs. &ldquo;This validation has led
to the expansion of our collaboration, said Tae Kyo Park, Founder and CEO of IntoCell. We will continue to cooperate closely with Cellectar
to accelerate the advancement of IntoCell-related PDC candidates into clinical trials.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About IntoCell and the OHPAS linker&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">IntoCell is a Korea-based
biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate (ADC) platform technologies
comprising scaffold moiety, ligands, toxins, linkers and conjugation methods. IntoCell has developed a novel self-immolative Ortho-Hydroxy
Protected Aryl Sulfate (OHPAS) linker that works with a wide variety of functional groups, triggering groups, and both phenolic and non-phenolic
payloads. The resulting ADCs have proven to be highly stable in chemical and biological environments and have demonstrated excellent potencies
in-vitro and in-vivo. IntoCell has also developed proprietary benzodiazepine dimers and modified duocarmycinoids that show high potency
with improved safety in preclinical models. IntoCell has created an OHPAS Linker-toxin Library containing a variety of toxins that can
be optimized for the fast delivery of a pre-clinical candidate in novel ADC programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Using its novel chemistries,
IntoCell is developing a pipeline of proprietary ADCs that includes a B7-H3 programme which is demonstrating excellent preclinical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit </FONT><U>http://www.intocell.co.kr</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cellectar Biosciences
is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently
and through research and development collaborations. The company&rsquo;s core objective is to leverage its proprietary Phospholipid Drug
Conjugate&trade; (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better
safety as a result of fewer off-target effects. The company&rsquo;s PDC platform possesses the potential for the discovery and development
of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development
collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The company&rsquo;s product
pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical
PDC chemotherapeutic programs and multiple partnered PDC assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit</FONT> <U>www.cellectar.com</U> and <U>www.wmclinicaltrial.com</U> or join the conversation by liking and
following us on the company&rsquo;s social media channels: <U>Twitter</U>, <U>LinkedIn,</U> and <U>Facebook</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This news release contains
forward-looking statements. You can identify these statements by our use of words such as &quot;may,&quot; &quot;expect,&quot; &quot;believe,&quot;
 &quot;anticipate,&quot; &quot;intend,&quot; &quot;could,&quot; &quot;estimate,&quot; &quot;continue,&quot; &quot;plans,&quot; or their
negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current
beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery
and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the
ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development
thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability
to maintain orphan drug designation in the United States for CLR 131, the volatile market for priority review vouchers, our pharmaceutical
collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product
pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic
reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2020. These forward-looking
statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Monique Kosse</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">212-915-3820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>monique@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2122116d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2122116d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !- /$# 2(  A$! Q$!_\0
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MTY\B]E'[,?L1M\*O[V_ZG'AYPYVJDOM2^V[_ !.WNFE^U5\1_&H\1^%/AO\
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>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
